Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain-Barré syndrome

Journal of Neuroimmunology

Volumn 139, Issue 1-2, 2003, Pages 133-140

  Dilley, A ^a   Gregson, N A ^a   Hadden, R D M ^a   Smith, K J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Campylobacter jejuni; Ganglioside; GM1; Nerve conduction

Indexed keywords

BACTERIUM ANTIBODY; GANGLIOSIDE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD3; GANGLIOSIDE GM1; GANGLIOSIDE GQ 1B; GANGLIOSIDE GT 1A; HUMORAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; CAMPYLOBACTER JEJUNI; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; MALE; NERVE BLOCK; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SPINAL ROOT;

EID: 0038382952     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(03)00156-5     Document Type: Article

References (52)

1. Allos B.M. Association between Campylobacter infection and Guillain-Barré syndrome. J. Infect. Dis. 176:1997;S125-S128.
2. Arasaki K., Kusunoki S., Kudo N., Kanazawa I. Acute conduction block in vitro following exposure to antiganglioside sera. Muscle Nerve. 16:1993;587-593.
3. Arasaki K., Kusunoki S., Kudo N., Tamaki M. The pattern of antiganglioside antibody reactivities producing myelinated nerve conduction block in vitro. J. Neurol. Sci. 161:1998;163-168.
4. Asbury A.K., Arnason B.G.W., Karp H.R., McFarlin D.F. Criteria for diagnosis of Guillain-Barré syndrome. Ann. Neurol. 3:1978;565-566.
5. Benatar M., Willison H.J., Vincent A. Immune-mediated peripheral neuropathies and voltage-gated sodiums channels. Muscle Nerve. 22:1999;108-110.
6. Berger A.R., Logigian E.L., Shahani B.T. Reversible proximal conduction block underlies rapid recovery in Guillain-Barré syndrome. Muscle Nerve. 11:1988;1039-1042.
7. Brinkmeier H., Wollinsky K.H., Hulser P.J., Seewald M.J., Mehrkens H.H., Kornhuber H.H., Rudel R. The acute paralysis in Guillain-Barré syndrome is related to a Na+ channel blocking factor in the cerebrospinal fluid. Pflugers Arch. 421:1992;552-557.
8. Brinkmeier H., Wollinsky K.H., Seewald M.J., Hulser P.J., Mehrkens H.H., Kornhuber H.H., Rudel R. Factors in the cerebrospinal fluid of multiple sclerosis patients interfering with voltage-dependent sodium channels. Neurosci. Lett. 156:1993;172-175.
9. Brinkmeier H., Aulkemeyer P., Wollinsky K.H., Rudel R. An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system. Nat. Med. 6:2000;808-811.
10. Buchwald B., Weishaupt A., Toyka K.V., Dudel J. Immunoglobulin G from a patient with Miller-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice. Neurosci. Lett. 201:1995;163-166.
11. Buchwald B., Dudel J., Toyka K.V. Neuromuscular blockade by immunoglobulin G from patients with Miller Fisher syndrome. Ann. N. Y. Acad. Sci. 841:1998;659-669.
12. Buchwald B., Toyka K.V., Zielasek J., Weishaupt A., Schweiger S., Dudel J. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study. Ann. Neurol. 44:1998;913-922.
13. Buchwald B., Bufler J., Carpo M., Heidenreich F., Pitz R., Dudel J., Nobile-Orazio E., Toyka K.V. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology. 56:2001;67-74.
14. Corbo M., Quattrini A., Latov N., Hays A.P. Localization of GM1 and Gal(beta 1-3)GalNAc antigenic determinants in peripheral nerve. Neurology. 43:1993;809-814.
15. Feasby T.E., Hartung H.P. Drain the roots: a new treatment for Guillain-Barré syndrome? Neurology. 57(5):2001;753-754.
16. Fisher M. Syndrome of ophthalmoplegia, ataxia and areflexia. New Engl. J. Med. 255:1956;57-65.
17. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann. Neurol. 22:1987;753-761.
18. Goodyear C.S., O'Hanlon G.M., Plomp J.J., Wagner E.R., Morrison I., Veitch J., Cochrane L., Bullens R.W., Molenaar P.C., Conner J., Willison H.J. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J. Clin. Invest. 104:1999;697-708.
19. Hadden R.D., Cornblath D.R., Hughes R.A., Zielasek J., Hartung H.P., Toyka K.V., Swan A.V. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann. Neurol. 44:1998;780-788.
20. Hadden R.D., Karch H., Hartung H.P., Zielasek J., Weissbrich B., Schubert J., Weishaupt A., Cornblath D.R., Swan A.V., Hughes R.A., Toyka K.V. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology. 56:2001;758-765.
21. Harrison B.M., Hansen L.A., Pollard J.D., McLeod J.G. Demyelination induced by serum from patients with Guillain-Barré syndrome. Ann. Neurol. 15:1984;163-170.
22. Harvey G.K., Toyka K.V., Zielasek J., Kiefer R., Simonis C., Hartung H.P. Failure of anti-GM1 IgG or IgM to induce conduction block following intraneural transfer. Muscle Nerve. 18:1995;388-394.
23. Hirota N., Kaji R., Bostock H., Shindo K., Kawasaki T., Mizutani K., Oka N., Kohara N., Saida T., Kimura J. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Brain. 120:1997;2159-2169.
24. Ho T.W., Li C.Y., Cornblath D.R., Gao C.Y., Asbury A.K., Griffin J.W., McKhann G.M. Patterns of recovery in the Guillain-Barré syndromes. Neurology. 48:1997;695-700.
25. Hughes R.A., Hadden R.D., Gregson N.A., Smith K.J. Pathogenesis of Guillain-Barré syndrome. J. Neuroimmunol. 100:1999;74-97.
26. Jacobs B.C., Rothbarth P.H., van der Meche F.G., Herbrink P., Schmitz P.I., De Klerk M.A., Van Doorn P.A. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 51:1998;1110-1115.
27. Jacobs B.C., Bullens R.W., O'Hanlon G.M., Ang C.W., Willison H.J., Plomp J.J. Detection and prevalence of alpha-latrotoxin-like effects of serum from patients with Guillain-Barré syndrome. Muscle Nerve. 25:2002;549-558.
28. Köller H., Buchholz J., Siebler M. Cerebrospinal fluid from multiple sclerosis patients inactivates neuronal Na+ current. Brain. 119:1996;457-463.
29. Kuwabara S., Yuki N., Koga M., Hattori T., Matsuura D., Miyake M., Noda M. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann. Neurol. 44:1998;202-208.
30. Kuwabara S., Asahina M., Koga M., Mori M., Yuki N., Hattori T. Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody. Neurology. 51:1998;1656-1660.
31. Kuwabara S., Mori M., Ogawara K., Mizobuchi K., Hattori T., Koga M., Yuki N. Axonal involvement at the common entrapment sites in Guillain-Barré syndrome with IgG anti-GM1 antibody. Muscle Nerve. 22:1999;840-845.
32. Low P.A., Schmelzer J.D., Dyck P.J. Results of endoneural injection of Guillain-Barre serum in Lewis rats. Mayo Clin. Proc. 57:1982;360-364.
33. Low P.A., Schmelzer J., Dyck P.J., Kelly J.J. Jr. Endoneurial effects of sera from patients with acute inflammatory polyradiculoneuropathy: electrophysiologic studies on normal and demyelinated rat nerves. Neurology. 32:1982;720-724.
34. Oomes P.G., Jacobs B.C., Hazenberg M.P., Banffer J.R., van der Meche F.G. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Ann. Neurol. 38:1995;170-175.
35. Paparounas K., O'Hanlon G.M., O'Leary C.P., Rowan E.G., Willison H.J. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain. 122:1999;807-816.
36. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 349:1997;225-230.
37. Plomp J.J., Molenaar P.C., O'Hanlon G.M., Jacobs B.C., Veitch J., Daha M.R., Van Doorn P.A., van der Meche F.G., Vincent A., Morgan B.P., Willison H.J. Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann. Neurol. 45:1999;189-199.
38. Redford E.J., Kapoor R., Smith K.J. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain. 120:1997;2149-2157.
39. Rees J.H., Soudain S.E., Gregson N.A., Hughes R.A. Campylobacter jejuni infection and Guillain-Barré syndrome. N. Engl. J. Med. 333:1995;1374-1379.
40. Rees J.H., Gregson N.A., Hughes R.A. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann. Neurol. 38:1995;809-816.
41. Roberts M., Willison H., Vincent A., Newsom-Davis J. Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. Lancet. 343:1994;454-455.
42. Santoro M., Uncini A., Corbo M., Staugaitis S.M., Thomas F.P., Hays A.P. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann. Neurol. 31:1992;385-390.
43. Sumner A., Said G., Idy I., Metral S. Electrophysiological and morphological effects of the injection of Guillain-Barré sera in the sciatic nerve of the rat. Rev. Neurol. (Paris). 138:1982;17-24.
44. Susuki K., Johkura K., Yuki N., Hasegawa O., Kuroiwa Y. Rapid resolution of nerve conduction blocks after plasmapheresis in Guillain-Barré syndrome associated with anti-GM1b IgG antibody. J. Neurol. 248:2001;148-150.
45. Takigawa T., Yasuda H., Kikkawa R., Shigeta Y., Saida T., Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers. Ann. Neurol. 37:1995;436-442.
46. Takigawa T., Yasuda H., Terada M., Haneda M., Kashiwagi A., Saito T., Saida T., Kitasato H., Kikkawa R. The sera from GM1 ganglioside antibody positive patients with Guillain-Barré syndrome or chronic inflammatory demyelinating polyneuropathy blocks Na+ currents in rat single myelinated nerve fibers. Intern. Med. 39:2000;123-127.
47. Thomas F.P., Trojaborg W., Nagy C., Santoro M., Sadiq S.A., Latov N., Hays A.P. Acta Neuropathol. 82:1991;378-383.
48. Uncini A., Santoro M., Corbo M., Lugaresi A., Latov N. Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve. 16:1993;610-615.
49. Weber F., Rudel R., Aulkemeyer P., Brinkmeier H. Anti-GM1 antibodies can block neuronal voltage-gated sodium channels. Muscle Nerve. 23:2000;1414-1420.
50. Weber F., Rudel R., Aulkemeyer P., Brinkmeier H. The endogenous pentapeptide QYNAD induces acute conduction block in the isolated rat sciatic nerve. Neurosci. Lett. 317:2002;33-36.
51. Wurz A., Brinkmeier H., Wollinsky K.H., Mehrkens H.H., Kornhuber H.H., Rudel R. Cerebrospinal fluid and serum from patients with inflammatory polyradiculoneuropathy have opposite effects on sodium channels. Muscle Nerve. 18:1995;772-781.
52. Yuki N. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome. J. Infect. Dis. 176:1997;S150-S153.